NasdaqCM - Nasdaq Real Time Price • USD
Affimed N.V. (AFMD)
At close: April 23 at 4:00 PM EDT
Pre-Market: 5:49 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -1.68 | -1.39 | -5.21 | -3.77 |
| Low Estimate | -1.92 | -1.61 | -6.53 | -5.35 |
| High Estimate | -1.58 | -0.99 | -3.26 | -2.62 |
| Year Ago EPS | -2.24 | -2.13 | -7.56 | -5.21 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 5 |
| Avg. Estimate | 1.15M | 960k | 5.62M | 6.54M |
| Low Estimate | 110k | -- | 1.17M | -- |
| High Estimate | 2.24M | 2.24M | 10.66M | 10.98M |
| Year Ago Sales | 5.06M | 1.47M | 8.82M | 5.62M |
| Sales Growth (year/est) | -77.30% | -34.60% | -36.30% | 16.40% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.08 | -2.02 | -1.97 | -1.64 |
| EPS Actual | -2.24 | -2.13 | -1.71 | -1.44 |
| Difference | -0.16 | -0.11 | 0.26 | 0.2 |
| Surprise % | -7.70% | -5.40% | 13.20% | 12.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.68 | -1.39 | -5.21 | -3.77 |
| 7 Days Ago | -1.67 | -1.39 | -5.2 | -3.76 |
| 30 Days Ago | -1.44 | -1.33 | -6.18 | -5.3 |
| 60 Days Ago | -0.14 | -0.13 | -0.62 | -0.53 |
| 90 Days Ago | -0.17 | -0.16 | -0.67 | -0.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AFMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.00% | -- | -- | 0.40% |
| Next Qtr. | 34.70% | -- | -- | 9.90% |
| Current Year | 31.10% | -- | -- | 4.30% |
| Next Year | 27.60% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/25/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/12/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Maintains | Truist Securities: Buy to Buy | 8/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
Related Tickers
ADAP Adaptimmune Therapeutics plc
1.1400
+12.87%
CRVS Corvus Pharmaceuticals, Inc.
1.5300
+6.25%
CLRB Cellectar Biosciences, Inc.
3.1100
-2.51%
PIRS Pieris Pharmaceuticals, Inc.
12.00
+2.67%
PRQR ProQR Therapeutics N.V.
2.0200
+1.00%
LPTX Leap Therapeutics, Inc.
3.2000
-0.31%
LVTX LAVA Therapeutics N.V.
2.9800
+4.56%
MREO Mereo BioPharma Group plc
2.7800
-0.36%
CTMX CytomX Therapeutics, Inc.
1.6800
+0.60%
ARWR Arrowhead Pharmaceuticals, Inc.
23.78
-0.59%